Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

COHANCE LIFESCIENCES LTD.

NSE : COHANCEBSE : 543064ISIN CODE : INE03QK01018Industry : Pharmaceuticals & DrugsHouse : Private

BSE1082.05-11 (-1.01 %)

PREV CLOSE ( ) 1093.05

OPEN PRICE ( ) 1119.95

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 8033

TODAY'S LOW / HIGH ( )1071.50 1119.95

52 WK LOW / HIGH ( )814.25 1359

NSE1083.35-13.65 (-1.24 %)

PREV CLOSE( ) 1097.00

OPEN PRICE ( ) 1090.00

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 1083.35 (1380)

VOLUME 211477

TODAY'S LOW / HIGH( ) 1072.95 1102.20

52 WK LOW / HIGH ( )815.05 1360

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 06-11 2018

Management Info

Vivek Sharma - Chairman V Prasada Raju - Managing Director

Registered Office

Address 215 Atrium, C Wing, 8th Floor, 819-821,Andheri, Kurla Road, Chakala,Andheri (East), Chakala Midc,
Mumbai,
Maharashtra-400093

Phone 022-61539999

Email info@suvenpharm.com

Website www.suvenpharm.com

Registrars Details

K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)

Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad

Listing : BSE, NSE

NEWS

20Jun Cohance Lifesciences enters into agree
Cohance Lifesciences has entered into an agreements with Chromo Laborato..

26May Cohance Lifesciences receives EIR from
Cohance Lifesciences has received the Establishment Inspection Report (E..

26May Cohance Lifesciences gains on receivin
Cohance Lifesciences is currently trading at Rs. 1094.55, up by 10.95 po..

25Apr Suven Pharmaceuticals informs about pr
Suven Pharmaceuticals has informed that it enclosed a copy of press rele..

28Feb Suven Pharmaceuticals informs about cr
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Re..

Financials

Rs. in Millions

	QTR Mar 25	ANNUAL 25
Net Profit	443.4	2717.1
Gross Profit	563.2	3513.5
Operating Profit	738.1	4165.5
Net Sales	3301.7	10935.1

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Blue Jet Healthcare (BSE) 1012.00 (4.21%)	M.Cap ( in Cr)17554.70
Jubilant Pharmova (BSE) 1234.90 (2.87%)	M.Cap ( in Cr)19669.63
Mercury Laboratories (BSE) 888.00 (3.71%)	M.Cap ( in Cr)106.56
Sanjivani Paranteral (BSE) 247.40 (11.39%)	M.Cap ( in Cr)303.91
Abbott India (BSE) 34148.85 (0.06%)	M.Cap ( in Cr)72563.92

Shareholding Pattern

	PROMOTERS	50.1%
	NON-INSTITUTION	22.23%
	MUTUAL FUNDS/UTI	13.04%
	FI/BANKS/INSURANCE	3.26%
	GOVERNMENT	0.01%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
DSP Healthcare Fund...	7.88
ITI Pharma & Health...	4.53
Mirae Asset Healthc...	3.61
UTI Healthcare Fund...	2.81
HDFC Pharma and Hea...	2.24
DSP Focused Fund-Reg(G)	2.17
Invesco India Focus...	2.17

Risk Disclosures on Derivatives

Smart Quotes

COHANCE LIFESCIENCES LTD.